Skip to main content
. 2012 Nov 29;2012:417017. doi: 10.1155/2012/417017

Figure 1.

Figure 1

MP ameliorates EAE when applied in a therapeutic setting but aggravates it in a preventive setting. (a) EAE was induced in C57Bl/6 mice by immunization with MOG35-55 and treated with different doses of MP for three consecutive days starting at an average score of 2-3 (marked by arrows). n = 5 for each group. All values are depicted as mean ± SEM; error bars for the two intermediate dose groups are omitted for reasons of clarity. Statistical analysis: days 10–27 after immunization (*P < 0.05, **P < 0.01). (b) In a preventive setting, 100 mg/kg MP was administered to C57Bl/6 mice on days −1, 0, and +1 of immunization (marked by arrows). n = 8 for each group. All values are depicted as mean ± SEM. Statistical analysis: days 7–20.